Biomet BMET
-
Mild Winter Decelerates Synthes Growth, J&J Offer Extended
… acquires Synthes as expected for CHF 159 per share. Late last week, the European Union gave its approval for the merger after Biomet agreed to purchase J&J's trauma business. U.S. antitrust regulators still have to weigh in on the deal, and J&J and …
-
TEXT-S&P comments on Biomet Inc
… based medical products manufacturer Biomet Inc. (B+/Stable/--) are not affected ..... with our expectations and will expand Biomet 's offerings in trauma, sports, and extremities. Also, Biomet had about $384 million of cash as of …
-
J&J ([[JNJ] -0.3%) receives a $280M offer for the trauma products ops of DePuy Orthopaedics from Biomet , a deal that J&J hopes will "satisfy all regulatory concerns" about its $21.3B purchase of ...
J&J ([[JNJ] -0.3% ) receives a $280M offer for the trauma products ops of DePuy Orthopaedics from Biomet , a deal that J&J hopes will "satisfy all regulatory concerns" about its $21.3B purchase of Synthes. Post your comment!
-
Biomet offers to acquire DePuy's trauma business
* Biomet makes $280 mln offer to buy DePuy trauma business
-
BIOMET /BRIEF (URGENT)
April 2 (Reuters) - Biomet Inc: * Moodys disclosures on credit ratings of Biomet Inc,
-
Integra Hitting That Same Ortho Wall
… big-cap names. Reality Bites Into The Third Quarter In an orthopedics world where hip, knee, and spine competitors like Biomet , JNJ, Medtronic, Stryker, Zimmer (NYSE: ZMH ), and Smith & Nephew (NYSE: SNN ) largely seem to be spinning their wheels …
-
The Trade that Killed Dighton Capital?
Biomet continues to show strength midway through fiscal 2005.
-
With Adjustments, Stryker Remains On Target to Meet Our Expectations
… valuation based on longer-term expectations, the firm's second-quarter results included a lot of unexpected factors. As at Biomet and Johnson & Johnson JNJ, Stryker's reconstructive results were a little better than we anticipated, partly due to bigger …
-
AstraZeneca (AZN) is in exclusive final talks to sell its Swedish healthcare and dental unit Astra Tech to Dentsply (XRAY) in a transaction that could value the subsidiary at about $1.8B, sources ...
… and dental unit Astra Tech to Dentsply ( XRAY ) in a transaction that could value the subsidiary at about $1.8B, sources say. Dentsply has outbid private equity group EQT Partners, medical company Biomet and others. Post your comment!
-
Wall Street Breakfast: Must-Know News
… sources said. Dentsply, a provider of dental equipment, has outbid private equity group EQT Partners, medical company Biomet and others. A deal could be announced as early as this week and would continue the re-emergence of strategic buyers, who …